<DOC>
	<DOC>NCT00871910</DOC>
	<brief_summary>Part 1 and Part 2 of this trial will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of SCH 727965 administered every 3 weeks as a 2 hour intravenous (IV) infusion (Part 1), and as an 8-hour or 24-hour IV infusion (Part 2). Each 3-week period is considered one treatment cycle. Part 3 of this trial will evaluate the effect of coadministration of antiemetic drug aprepitant on the pharmacokinetics of SCH 727965 administered as a 2 hour IV infusion once every 3 weeks.</brief_summary>
	<brief_title>Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age &gt;=18 years, either sex, any race. Subjects must have histologically proven solid tumors, nonHodgkin's lymphoma, or multiple myeloma. There must be no known standard therapy, or disease must be refractory to standard therapy. Eastern Cooperative Oncology Group performance status of 0, 1, or 2. Adequate hematologic, renal, and hepatic organ function and laboratory parameters. Symptomatic brain metastases or primary central nervous system malignancy. Previous radiation therapy to &gt;25% of the total bone marrow. Previous treatment with SCH 727965. Known HIV infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>